| 18.96 0.45 (2.43%) | 08-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.36 | 1-year : | 26.12 |
| Resists | First : | 19.14 | Second : | 22.36 |
| Pivot price | 18.68  |
|||
| Supports | First : | 18.52 | Second : | 18.13 |
| MAs | MA(5) : | 18.95 | MA(20) : | 18.66 |
| MA(100) : | 18.29 |
MA(250) : | 13.23 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 81.1 | D(3) : | 81.1 |
| RSI | RSI(14): 60.2 | |||
| 52-week | High : | 19.5 | Low : | 4.18 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MOR ] has closed below upper band by 21.1%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19 - 19.1 | 19.1 - 19.17 |
| Low: | 18.69 - 18.83 | 18.83 - 18.93 |
| Close: | 18.78 - 18.97 | 18.97 - 19.13 |
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Mon, 15 Jul 2024
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR - PR Newswire
Thu, 20 Jun 2024
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders - Business Wire
Thu, 06 Jun 2024
MorphoSys AG Announces Major Leadership Changes - TipRanks
Mon, 29 Apr 2024
MorphoSys AG Reports First Quarter 2024 Financial Results - Business Wire
Thu, 11 Apr 2024
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis - Business Wire
Tue, 06 Feb 2024
Novartis And MorphoSys Are A Perfect Match - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 151 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 7.4 (%) |
| Shares Short | 262 (K) |
| Shares Short P.Month | 293 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.97 |
| Profit Margin | -190.7 % |
| Operating Margin | -960.2 % |
| Return on Assets (ttm) | -13.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 13.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.6 |
| EBITDA (p.s.) | -2.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -284 (M) |
| Levered Free Cash Flow | 99 (M) |
| PE Ratio | -12.64 |
| PEG Ratio | 0 |
| Price to Book value | -2.73 |
| Price to Sales | 11.82 |
| Price to Cash Flow | -10.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|